News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Cipla has a robust governance model focused on sustainability
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Subscribe To Our Newsletter & Stay Updated
